Does Cosentyx Effectively Treat Nail Psoriasis?
Cosentyx (secukinumab), an IL-17A inhibitor, reduces nail psoriasis symptoms in clinical trials. In the TRANSFIGURE study, 47% of patients achieved near-complete or complete nail clearance (mNAPSI 0 or ≤1) after 16 weeks, rising to 62% at 40 weeks.[1] Real-world data shows 30-50% improvement in nail psoriasis severity scores after 6-12 months.[2] It targets inflammation driving nail changes like pitting, onycholysis, and hyperkeratosis.
How Quickly Does It Work for Nails?
Nail improvements lag behind skin clearance, often starting at 12-16 weeks and peaking at 6-12 months. In trials, 20-30% saw major reductions by week 16, with sustained gains through year 1.[1][3] Patient reports note gradual thickening reduction and pitting fade.
How Does It Compare to Other Biologics?
| Treatment | Nail Clearance Rate (16 weeks) | Key Edge |
|-----------|-------------------------------|----------|
| Cosentyx | 47% (mNAPSI ≤1) [1] | Strong for enthesitis-linked nail issues |
| Ixekizumab (Taltz) | 50-55% [4] | Similar IL-17 speed |
| Adalimumab (Humira) | 25-35% [5] | Slower for nails |
| Risankizumab (Skyrizi) | 40% [6] | Better skin but comparable nails |
Cosentyx outperforms TNF inhibitors like Humira but matches other IL-17/23 drugs.
Common Side Effects in Nail Psoriasis Patients
Upper respiratory infections (10-15%), candidiasis (3-5%), and injection-site reactions occur most.[7] Nail-specific risks are low, but monitor for worsening onycholysis early. Long-term use (up to 5 years) shows no new safety signals.[3]
Who Responds Best and When to Expect Results?
Patients with moderate-severe nail psoriasis (mNAPSI >20) and PsA see 60-70% response rates.[1] Non-responders by week 16 rarely improve later—switch biologics then. Combine with topicals like calcipotriene for faster nail bed clearance.
Cost and Access for Nail Psoriasis
Monthly cost: $5,000-$6,000 without insurance; copay cards cap at $5/month for eligible.[8] Covered for plaque psoriasis including nails if failed topicals. No specific nail-only approval, but used off-label effectively.
Sources
[1] TRANSFIGURE study (JAMA Dermatol, 2019)
[2] Real-world evidence (J Eur Acad Dermatol Venereol, 2021)
[3] 5-year safety data (Ann Rheum Dis, 2022)
[4] Ixekizumab nail trial (Br J Dermatol, 2020)
[5] Adalimumab meta-analysis (J Am Acad Dermatol, 2018)
[6] Risankizumab phase 3 (Lancet, 2020)
[7] Cosentyx prescribing info (Novartis)
[8] GoodRx pricing